FINEARTS-HF Meets Primary Endpoint

Bayer announced today that the FINEARTS-HF Trial met the primary endpoint and significantly reduced cardiovascular death and worsening heart failure events in patients with heart failure and LVEF of 40% or higher.

https://www.bayer.com/media/en-us/finerenone-meets-primary-endpoint-in-phase-iii-finearts-hf-cardiovascular-outcomes-study-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/